Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105714 | 0.98 | ALDH1A1 (0.54) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL27768674 | 0.89 | FAAH (0.55) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL892926 | 0.84 | TUBB4A (0.59) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| Lithium Ion SCHEMBL5105709 | 0.84 | FAAH (0.52) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL4790263 | 0.83 | TUBB4A (0.57) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL14192604 | 0.81 | FAAH (0.50) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL5109428 | 0.80 | FAAH (0.49) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL5111369 | 0.79 | FAAH (0.56) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL2779211 | 0.79 | FAAH (0.71) | FAAHCES1 | |
| SCHEMBL2724814 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KDM4ENPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630133-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | Bayer Intellectual Property GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012052412-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2012-04-26 | — | — | WO | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1699801-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061510-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | ALDH1A1 1028/4885KDM4E 2378/4885NPC1 1205/4885 |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNB1, CHRNA2 | ALDH1A1 500/4885KDM4E 3396/4885NPC1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.